AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05765864 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lifetime Incidence of Traumatic Events questionnaire (LITE)
Description: Is a short checklist for screening and assessing the exposure to trauma in children and adolescents. It covers a broad range of potentially upsetting situations that can cause trauma to children and adolescents, such as a car accident, fire, death of a family member, exposure to threats, sexual assault, or witnessing violence. The questionnaire had been validated on a Slovene population of children and adolesscents.~Greenwald R, Rubin A. Assessment of posttraumatic symptoms in children:~development and preliminary validation of parent and child scales. Res Soc Work Pract. (1999) 9:61-75. doi: 10.1177/104973159900900105 Uršicˇ K, Bucik V, Klemencˇ icˇ S, Bratina N, Battelino T, Dovcˇ K and Drobnicˇ Radobuljac M (2021) Validation of the Lifetime Incidence of Traumatic Events (LITE-S/P) Questionnaires in Children and Adolescents in Slovenia. Front. Psychiatry 12:665315. doi: 10.3389/fpsyt.2021.665315
Study NCT05765864 — intervention group
Intervention type: GENETIC
Intervention: Genetic methods
Description: DNA isolation, Sequencing, Libraries preparation, Analisys; Bioinformatics (Base Calling, Variant Calling, Quantification and evaluation of short tandem repetitions, Methylation sites detection).
Study NCT05662176 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Supportive Care based on trauma informed care
Description: Participants were provided care in different rooms, blinded to the differences in practice used between the two groups. In the same clinic, a room was designed as a positive delivery room by the researchers and a relaxing environment was created. In this room, supportive care based on trauma informed care was provided to the experimental group during birth.
Study NCT05662176 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standart care
Description: Participants in the control group, on the other hand, received the routine care given in the hospital by other midwives in the clinic, and there was a change of caregiver midwife during shift changes. The care provided in the hospital during delivery is mostly focused on low level of physical comfort and high level of follow-up.
Study NCT06020118 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Simultaneous Vaccination (Influenza Vaccine and mRNA COVID booster)
Description: Influenza vaccination and mRNA COVID-19 booster will be given at Visit 1.
Study NCT06020118 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sequential Vaccination (Influenza vaccine then mRNA COVID booster)
Description: Influenza vaccine will be given at Visit 1 and mRNA COVID booster will be given at Visit 2.
Study NCT06020118 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sequential Vaccination (mRNA COVID booster then Influenza vaccine)
Description: mRNA COVID booster will be given at Visit 1 and Influenza vaccine will be given at Visit 2.
Study NCT05173181 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Flexible intramedullary nail
Description: Fixation of distal ulna fracture with flexible intramedullary nail
Study NCT05366452 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMPELLA CP
Description: Implantation of the IMPELLA CP will be performed using the femoral route in most patients. Echo guided puncture to gain access for IMPELLA CP will be encouraged and a local angiography will be promoted to check the feasibility of device implantation. The implantation will follow gold standard after obtaining an ACT >250 s. As soon as the device is in place it will be started.
Study NCT05366452 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: The patients will receive up to date management according to the consensus of care regarding inotropes and vasopressors in CS (2,4). A dedicated protocol will ensure that management is similar between centers and in both groups. The shock team will be in charge of all therapeutic decisions.
Study NCT05276362 — intervention group
Intervention type: DEVICE
Intervention: Study Watch
Description: The Study Watch is an investigational wrist worn wearable device made with biocompatible contact materials containing various sensors capable of continuous recording of physiological, activity, and environmental data.
Study NCT05276362 — intervention group
Intervention type: DEVICE
Intervention: Actiwatch
Description: The Actiwatch is a wrist worn activity device designed to collect general activity and sleep information. This device received 510(k) clearance from the FDA as a wearable medical data collection device for research and clinical use.
Study NCT06583044 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: It includes 33 questions measuring awareness and knowledge about bruxism.
Study NCT06581354 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PROVISIONALIZATION
Description: glass fiber composite as a temporary framework followed by PEKKTON definitive framework.
Study NCT06581354 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PROVISIONALIZATION
Description: glass fiber composite as a temporary framework followed by PEKKTON definitive framework.
Study NCT06397248 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT05564455 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biometry with Kane formula
Description: Kane formulae for intraocular lens (IOL) power calculation in cataract patients
Study NCT05564455 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biometry with SRK-T formula
Description: Sanders Retzlaff Kraff theoretical (SRK T) formulae for intraocular lens (IOL) power calculation in cataract patients
Study NCT05498558 — intervention group
Intervention type: OTHER
Intervention: No intervention.
Description: No intervention.
Study NCT05973916 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive intervention
Description: cleaning of patients' rooms will be subjected to a comprehensive intervention, consisting of: 1) a patient's unit commando team for daily and for terminal cleaning, 2) all lights in patients' room are VYV led lights, and 3) in each room, a QleanAir Scandinavia® filtering machine will be placed.
Study NCT05652985 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inter-professional Collaboration Training
Description: the participated nurses will receive session about Inter-professional Collaboration followed by activity which can boost Inter-professional Collaboration
Study NCT05473468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib
Description: a single oral dose of \[14C\]famitinib (25 mg/150 uCi suspension)
Study NCT04555798 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Meropenem Injection
Description: patients of both groups given meropenam 1 gram every 8 hours till we collect the sputum culture
Study NCT04555798 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem Injection
Description: patients of both groups given meropenam 1 gram every 8 hours till we collect the sputum culture
Study NCT04555798 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: A-V ECMO
Description: Only patients of group B connected to A-V ECMO for two weeks
Study NCT05129527 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InspirerMundi app
Description: Patients in the experimental group, in addition to usual care, will be invited to use the InspirerMundi app for 4 months to support adherence to preventive inhaled medication and their asthma self-management. The purpose of the InspirerMundi app is to transform the adherence process into a positive experience through immediate and pleasant rewards. The InspirerMundi app integrates 3 main components: monitoring (symptoms, control, adherence), gaming and social/peer support.~Participants will be able to include their action plan in the app. Within the action plan, the application can lead to changes in the medication effectively taken, which means that the therapeutic level can be adjusted according to the action plan.~Participants in the experimental arm will be able to share with their physician, through the app, their medication adherence and asthma control data in the 3 months visit, and whenever patients wish during the study period.
Study NCT05129527 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual care will consist of pharmacological treatment and medical monitoring through routine medical visits.
Study NCT05129527 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care will consist of pharmacological treatment and medical monitoring through routine medical visits.
Study NCT05595460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RYZ101 Dose Level 1
Description: Dose Level 1
Study NCT05595460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RYZ101 Dose Level 2
Description: Dose Level 2
Study NCT05595460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RYZ101 Dose Level 3
Description: Dose Level 3
Study NCT05595460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RYZ101 Dose Level -1
Description: Dose Level -1
Study NCT05595460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab
Study NCT05595460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin
Study NCT05595460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide
Study NCT05308979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 100 UNT [Botox]
Description: Intradetrusor (Bladder) Botox Injection at 1 vs 10 injection sites
Study NCT05308979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OnabotulinumtoxinA 100 UNT [Botox]
Description: Intradetrusor (Bladder) Botox Injection at 1 vs 10 injection sites
Study NCT05824078 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic surgery
Description: Arthroscopic approach involves smaller incision, offering less traumatic procedures and faster healing, but due to the limited space in this closed field with significant vasculature and nerve distribution, scoping has increased risk for iatrogenic injuries.
Study NCT05824078 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Surgery
Description: The open approach requires dissection of capsuloligamentous structures, which can lead to stiffness of the joint due to capsular scarring as it heals. However, it offers good visual field when treating the injury, allowing maneuverability to avoid iatrogenic soft tissue injuries.
Study NCT05333133 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high calorie formula (oral nutritional supplement/ONS)
Description: every subject is given 400 ml (equal with 400 kcal) high calorie formula for 90 days. before (day 0) and after (day 91) the intervention was enrolled, blood samples was taken to investigate IGF-1 and total lymphocyte counts.~The body weight and body height will be measured at day-0, day-14, day-30, day 60 and 90.
Study NCT05118841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX-4081
Description: Twice daily (BID), oral dosing of ZX-4081 at the assigned dose level in a 28-day cycle
Study NCT05208021 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group (Motivational Interviewing)
Description: The Health Promotion Model and the Motivational Interview-Based Health Protection and Promotion Program were applied to the experimental group, which consisted of 6 sessions and lasted an average of 60-120 minutes. Sessions were held in the form of individual interviews due to the pandemic and social distance conditions.
Study NCT04927065 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.211
Description: Sterile liquid for injection
Study NCT04927065 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273
Description: Sterile liquid for injection
Study NCT04927065 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.617.2
Description: Sterile liquid for injection
Study NCT04927065 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.213
Description: Sterile liquid for injection
Study NCT04927065 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.529
Description: Sterile liquid for injection
Study NCT05024266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Participants received 2 cycles Tislelizumab 200mg d1 + Albumin Paclitaxel 260mg/m2 d1 + Carboplatin AUC5 d1 every 3 weeks, and then were evaluated for surgery.
Study NCT04927065 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.214
Description: Sterile liquid for injection
Study NCT04927065 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.222
Description: Sterile liquid for injection
Study NCT04927065 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.815
Description: Sterile liquid for injection
Study NCT04927065 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.231
Description: Sterile liquid for injection
Study NCT05206916 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: cryotherapy
Description: Cryotherapy at sites of vibration as origin of snoring and site of collapse for patients with obstructive sleep apnea syndrome
Study NCT05524935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab Day 1 of each 21 day (3 week) cycle
Study NCT04980599 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotic drink with Lactobacillus paracasei K56
Description: Probiotic drink (K56 10\^11CFU) 350ml/d for 60days
Study NCT04980599 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: maltodextrin
Description: maltodextrin ,for 60days
Study NCT04980599 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic powder E3
Description: Probiotic powder 3.0g/d (K56 10\^10cfu) 60days;
Study NCT04980599 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic powder E5
Description: probiotic powder 8g/day for 60days
Study NCT04980599 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotic capsule E7
Description: probiotic k56 capsule, 2capsules/d (10\^7cfu) for 60days
Study NCT04980599 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotic capsule E9
Description: probiotic k56 capsule, 2capsules/d (10\^9cfu) for 60days
Study NCT04980599 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotic capsule E10
Description: probiotic k56 capsule, 2capsules/d (10\^10cfu) for 60days
Study NCT04980599 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotic capsule E11
Description: probiotic k56 capsule, 4capsules/d (10\^11cfu) for 60days
Study NCT06566742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olutasidenib
Description: Given by PO
Study NCT06651034 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: Under aseptic measures, a phlebotomist obtained the blood in vacutainers. Vacutainers was centrifuged and middle zone containing platelet rich plasma was aspirated in a 5 ml disposable syringe. The patient received intralesional injection
Study NCT05524935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib by mouth days 1-21 of each 21 day (3 week) cycle
Study NCT06647121 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT Psychoeducational Workshop
Description: The 1-hour ACT psychoeducational workshop will introduce participants to Acceptance and Commitment Therapy and include guided practice of the mindfulness exercise that they will be asked to practice for two weeks.
Study NCT06647121 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ACT Psychoeducational Workshop
Description: The 1-hour ACT psychoeducational workshop will introduce participants to Acceptance and Commitment Therapy and include guided practice of the mindfulness exercise that they will be asked to practice for two weeks.
Study NCT06647121 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACTaide Mobile App
Description: The ACTaide mobile app is a novel app that is designed to support home practice of exercises from ACT via annotated image sequences and reminder notifications. A prototype version that features the dropping anchor mindfulness exercise will be investigated in this study.
Study NCT06647121 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reminders-only mobile app
Description: This app will include only reminder notifications to encourage home practice of the dropping anchor mindfulness exercise in the comparator condition. It will not include the annotated image sequence for the exercise (i.e., the primary feature of the ACTaide app to be investigated in the intervention condition).
Study NCT06377059 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WARD
Description: Heart rate and respiratory rate is measured using Isansys lifetouch (Isansys Lifecare, Oxfordshire, UK), single-lead ECG monitor. An ECG is recorded as a 10-second segment every minute. Heart rate is derived once per minute from the R-R interval, and similarly, the RF is calculated from the changes in thoracic impedance once per minute. Blood pressure is monitored with either Meditech BlueBP-05 (Meditech Ltd., Budapest, Hungary) or A\&D TM-2441 (A\&D company Ltd., Tokyo, Japan). Both are non-invasive oscillometric, cuff-based blood pressure monitoring devices. Peripheral oxygen saturation was measured with NonIn WristOx 3150 (Nonin Medical Inc., Minnesota, USA) pulse oximeter, which is a photoplethysmograph with a sampling frequency of 75 Hz.
Study NCT05913609 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Yaari Extractor
Description: The Yaari Extractor device is a single-use prescription device for neonatal extraction in deliveries that are complicated by shoulder dystocia. The Study Device consists of two curved, rigid plastic-coated metal Arms with Handles which are used for control of the device outside the body, and an elastic Engagement Element which conforms to the maternal and neonatal anatomy, and which is used for direct contact with the entrapped neonate within the birth canal.
Study NCT05725928 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobility technician
Description: Designated mobility technicians (MT) will ambulate hospitalized medical patients up to 3 times daily, 7 days per week, until discharge or a maximum of 10 days. Each day, the MT will visit the patient 4 times or until the patient successfully ambulates 3 times that day. In cases where a PT has provided a recommendation in the patient's chart, the MT will follow the recommendation, if feasible. Otherwise, the MT will execute the standard mobility protocol. The mobility protocol will allow the MT to assist a patient with an appropriate out-of-bed activity based on their 6-clicks score from the immediately preceding session.
Study NCT06686888 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SCFA
Description: On test days participants will ingest the capsules during a standard no fiber breakfast. Blood samples will be collected at regular time points for 8 hours. A visual analogue scale that questions hunger and satiety will be completed at regular time points.
Study NCT06686888 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: microcristalline cellulose
Description: On test days participants will ingest the capsules during a standard no fiber breakfast. Blood samples will be collected at regular time points for 8 hours. A visual analogue scale that questions hunger and satiety will be completed at regular time points.
Study NCT06634199 — intervention group
Intervention type: DRUG
Intervention: Durvalumab
Description: Chemo-radiotherapy + Durvalumab for non-resectable stage III NSCLC patients according to clinical practice of each participant hospital
Study NCT06721702 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: Motivational interviews were administered as the intervention of the research. Motivational interviewing consists of two stages. In the first stage, the four principles of motivational interviewing (developing contradiction, showing empathy, supporting self-efficacy, and resolving resistance) are aimed at providing motivation in individuals. The second stage is strengthening the commitment to change.
Study NCT06721923 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary protein
Description: Beneprotein powder, a whey-based supplement, will be used in both arms. Intervention dose will be 1g/kg of dietary protein (or 1.2g/kg of the powder), provided to both arms with different modes of delivery.
Study NCT06721923 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary protein
Description: Beneprotein powder, a whey-based supplement, will be used in both arms. Intervention dose will be 1g/kg of dietary protein (or 1.2g/kg of the powder), provided to both arms with different modes of delivery.
Study NCT06720181 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Resting-state Functional Magnetic Resonance Imaging and Diffusion Tensor Magnetic Resonance Imaging of the brain
Study NCT06720324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine + Cyclophosphamide + CD7-specific CAR-T Cells
Description: fludarabine 30 mg/kg on day -5, -4, and -3; cyclophosphamide 300 mg/kg on day -5, -4, and -3; CD7-specific CAR-T Cells on day 0.
Study NCT06721494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methamphetamine
Description: Methamphetamine HCl for intravenous administration